Karuna raises $42M to resurrect abandoned Lilly drug for schizophrenia

Karuna Pharmaceuticals has the cash it needs to start mid-stage trials of an Eli Lilly drug, shelved because of side effects, as part of a combination therapy for schizophrenia and Alzheimer’s.